Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

We present the preliminary toxicity data from the MRC COIN trial, a phase III randomised controlled trial of first-line therapy in advanced colorectal cancer, with particular reference to the addition of cetuximab to an oxaliplatin–fluoropyrimidine combination. A total of 804 patients were randomise...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, R A, Meade, A M, Madi, A, Fisher, D, Kay, E, Kenny, S, Kaplan, R S, Maughan, T S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634710/
https://www.ncbi.nlm.nih.gov/pubmed/19165196
http://dx.doi.org/10.1038/sj.bjc.6604877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634710/
https://www.ncbi.nlm.nih.gov/pubmed/19165196
http://dx.doi.org/10.1038/sj.bjc.6604877

Ejemplares similares